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Abstract 
Background: Smoking is associated with increased macrovascular and microvascular complications in people with 
diabetes. In addition to other concomitant vascular perturbations, it also seems to influence the cardiometabolic 
parameters, which may partly explain the accelerated rate of vascular complications in smokers with diabetes. While 
smoking cessation is advocated as a universal component of the management of diabetes, there is some anecdotal 
evidence that HbA1c could increase following smoking cessation. The aim of this review is to explore the relationship 
between smoking and its cessation on cardiometabolic parameters in diabetes.
Methods: Searches were conducted on Medline, EMBASE and CINAHL up to March 2016. After screening 6866 stud-
ies (Additional file 1), 14 observational studies with a total of 98,978 participants’ with either type 1 or type 2 diabetes 
were selected for review. Narrative synthesis and meta-analyses were carried out to explore the relationship between 
smoking and its cessation.
Results: Meta-analysis showed that the pooled mean difference of HbA1c between non-smokers and smokers was 
−0.61% (95% CI −0.88 to −0.33, p < 0.0001). The difference in LDL cholesterol between non-smokers and smokers 
was −0.11 mmol/l (95% CI −0.21 to −0.01, p = 0.04). The difference in HDL cholesterol between non-smokers and 
smokers was 0.12 mmol/l (95% CI 0.08–0.15, p < 0.001). However, there was no statistically significant difference in 
blood pressure between the two groups. The difference in HbA1c between quitters and continued smokers was not 
statistically significant −0.10% (95% CI −0.42 to 0.21, p = 0.53). However, a narrative synthesis revealed that over a 
period of 10 years, the HbA1c was comparable between non-smokers and quitters.
Conclusion: Non-smokers have a statistically significant lower HbA1c and more favourable lipid profile compared to 
smokers. Smoking cessation does not lead to an increase in HbA1c in long-term and may reduce vascular complica-
tions in diabetes by its favourable impact on lipid profile.
Keywords: Smoking, Smoking cessation, Glycosylated haemoglobin (HbA1c), Diabetes, Low density lipoprotein 
(LDL) and high density lipoprotein (HDL) cholesterol: blood pressure (systolic and diastolic—SBP and DBP)
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Background
Despite an overwhelming body of evidence against smok-
ing and all-out efforts to control tobacco-related harm, 
globally approximately 6 million deaths are attributed 
to use of tobacco every year [1]. If the current trend of 
smoking continues, the World Health Organisation 
(WHO) estimates that by 2030, the annual death toll will 
rise to over 10 million [2]. Smoking appears to positively 
contribute to glucolipotoxicity and insulin resistance, 
which are the hallmarks of diabetes. Nicotine and the 
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free radicals in cigarettes have been linked to accelerated 
β-cell apoptosis and impedance of intracellular GLUT-4 
mobilisation, which may feed into hyperglycaemia asso-
ciated with diabetes [3–5]. A number of studies have 
demonstrated that smoking is associated with increased 
cardiovascular mortality in people with diabetes [6, 7]. 
However, it is not entirely clear whether this increased 
mortality in smokers is due to atherogenic metabolic 
profile or due to the direct toxic effects of nicotine and 
other toxic substances in cigarettes on the cardiovascular 
milieu.
The European Association for Study of Diabetes 
(EASD) and the American Diabetes Association (ADA) 
recommend smoking cessation as an integral component 
of the management of diabetes [8]. Other international 
and national guidelines, including the World Health 
Organization (WHO), the National Institute for Health 
and Care Excellence (NICE) and the Scottish Intercolle-
giate Guidelines Network (SIGN) in the UK, have pub-
lished similar recommendations [9, 10]. Despite multiple 
recommendations, the prevalence of smoking in people 
with and without diabetes remains comparable [11]. One 
of the commonest arguments against quitting in people 
with diabetes is the risk of weight gain and worsening gly-
caemic control after quitting [12, 13]. Some studies have 
demonstrated a positive correlation between weight gain 
and increased HbA1c after quitting [14, 15]. Interestingly, 
a number of studies also demonstrated a positive correla-
tion between smoking cessation and developing diabetes 
suggesting that smoking cessation may have a detrimen-
tal impact on glucose metabolism [16–18]. Due to the 
risk of weight gain and the potential risk of worsening 
glycaemic control, there is a significant anxiety about the 
benefit of smoking cessation in people with diabetes [19, 
20]. The aim of this systematic review and meta-analysis 
was to explore the precise relationship of the cardiometa-
bolic profiles in smokers, non-smokers, and quitters with 
diabetes.
Definition of outcomes and comparisons
For this study, HbA1c was defined as the average plasma 
glucose level over the preceding 3 months period, meas-
ured by high-performance liquid chromatography 
(HPLC) and expressed as the ratio to total haemoglobin 
in percentage. NICE recommends the target range for 
HbA1c for people with diabetes, taking into considera-
tion other vascular risk factors and co-morbidities, to be 
6.5–7.5%. In this study for lipid profiles we focused on 
high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C). HDL-C is the 
cardioprotective cholesterol, which plays a pivotal role in 
removing the harmful fat particles from the circulation 
and protects from cardiovascular events. The normal 
range of HDL-C is 1.3–1.5 mmol/l. LDL-C, on the other 
hand, is atherogenic cholesterol, which causes athero-
sclerosis and thromboembolic events (normal range 
of LDL-C is 2.59–3.34  mmol/l). Smokers were defined 
as self-reported smokers who smoked cigarettes for at 
least 12  months, without any biochemical verifications. 
Non-smokers were defined as people who never smoked 
cigarettes. Quitters were former cigarette smokers 
who gave-up after smoking for at least 12  months, and 
remained abstinent for at least 12  months. The ration-
ale for using these criteria was, in order to observe any 
meaningful change in cardiometabolic parameters, it was 
deemed to be a bare minimum length of time. People 
with diabetes was defined as those individuals who had 
an HbA1c of ≥6.5% or being treated with glucose lower-
ing medications, irrespective of their HbA1c value.
Methods
Search strategy and selection criteria
In order to explore the relationship of HbA1c, lipid pro-
files and blood pressure in smokers vs. non-smokers and 
smokers vs. quitters, we carried out a comprehensive 
database search. Prior to embarking upon a full search, 
we carried out a scoping search on Cochrane Library 
(4th March 2016, using the search terminology diabetes 
AND smoking AND glycaemia and/or lipid profile and/
or blood pressure). We also searched PROSPERO, Pub-
med, and Google Scholar but did not find any published 
or on-going reviews with similar aims. We assessed the 
titles of the articles for suitability for inclusion using the 
acronym PECO—population (people with diabetes); 
exposure (cigarette smoking); comparison (not smoking 
and/or quitting) and outcome (HbA1c, lipid profile and 
blood pressure).
The search was conducted on EMBASE (1978 to March 
2016), and CINAHL (1981 to March 2016) (Additional 
file  1) and OVID/Medline (from 1946 to March 2016) 
(Additional file 2). The focus of our search was to iden-
tify three separate themes of medical subject headings 
(MeSH): smoking status (current smokers, never smokers 
and quitters), type 1 and type 2 diabetes and HbA1c, lipid 
profile and/or blood pressure. The three themes were 
then combined using the Boolean operator “and”, impos-
ing no restrictions on type of diabetes or age of the par-
ticipating subjects to capture as much data as possible. 
The detailed search strategy using PRISMA flow chart is 
shown in Fig.  1. In addition, a hand search was carried 
out on the bibliography of a number of review articles, 
to identify any relevant publications [21, 22]. Review pro-
tocol, inclusion, and exclusion criteria were agreed with 
the review team and were published in the International 
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Prospective Register of Systematic Review. This system-
atic review and meta-analysis were reported following 
the PRISMA and MOOSE guideline [23, 24].
Inclusion criteria
1. Participants with either type 1 or type 2 diabetes.
2. HbA1c and/or lipid profiles and/or blood pressure 
were reported as the outcomes.
3. Participants were classified as smokers, non-smokers 
or quitters.
4. Studies were reported in English language.
5. Newcastle-Ottawa quality scale for observational 
studies score >5.
Exclusion criteria
1. Any other types of diabetes apart from type 1 or type 
2 diabetes.
2. Review articles and meeting abstracts without any 
relevant data.
3. Studies not in English language.
4. Smoking status not recorded or smokers of less than 
12-months duration or quitters not abstinent for at 
least 12 months.
5. Newcastle-Ottawa quality scale for observational 
studies score <5.
6. Reported association without any retrievable data.
Records identified through 
database searching
Medline – 3628; CINAHL –
1825; EMBASE - 1393
(n = 6866)
Additional records identified through 
other sources including grey literature
(n = 20)
Records after duplicates removed
(n = 6826)
Records screened with title and 
abstracts
(n = 6826)
Records excluded
(n = 6669)
Not reporting diabetes, 
smoking and/or smoking 
cessation and/or 
Full-text articles assessed for 
eligibility
(n =57)
Full-text articles excluded, not 
observational study, 
conference abstracts with not 
data, review articles
(n = 43)
Studies included in qualitative 
synthesis
(n = 14)
Studies included in quantitative 
synthesis (meta-analysis)
(n = 10)
Fig. 1 PRISMA flow chart
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Study selection
Two investigators (DK and FZ) assessed the eligibility of 
the studies using the inclusion and exclusion criteria. A 
third investigator (DW) resolved any discrepancies in the 
opinions of the two other investigators. DK and CG inde-
pendently extracted the data and came to a consensus 
concerning data accuracy.
Data extraction and quality assessment
We made an a priori decision to select observational 
cross-sectional, prospective and retrospective studies. 
As the heterogeneity between observational studies is 
likely to be high, random effects models were fitted for 
the meta-analyses. We extracted the data using a pre-
designed data extraction template describing the study 
characteristics and the reported results. All the vari-
ables were converted to the same units i.e. for HbA1c 
described in mmol/l was converted to % using the 
standard conversion chart; lipid profiles reported in 
mg/dl were converted to mmol/l using the formula 
(mg/dl = ×0.0555 =  mmol/l) and blood pressure were 
reported as mm of Hg. If the information was unavail-
able or unclear from the published literature, we con-
tacted the study authors for clarification. For the data 
quality of individual studies, we used the Newcastle-
Ottawa quality assessment scale used for observational 
studies [25].
Statistical analysis
Narrative synthesis, meta-analysis and meta-regression 
(Additional file  3) were conducted depending on the 
availability of suitable data. Narrative synthesis is primar-
ily based on the descriptive analysis of individual studies 
and is a useful tool to summarise the findings, even if the 
results cannot be pooled together for meta-analysis. A 
narrative synthesis is an integral component of any sys-
tematic review irrespective of whether a meta-analysis 
can be carried out or not. Meta-analysis, on the other 
hand, is a comprehensive method of statistical analysis by 
collating data from a number of studies to give a pooled 
estimate of the effect size. Meta-regression models were 
fitted to assess the relationship between the study effect 
size and study level covariates, allowing heterogeneity 
between study results to be better understood.
For this study, the significance level for heterogene-
ity was set at p < 0.1 and for overall effect size p < 0.05. 
Cochrane Review Manager Version 5 was used for the 
meta-analysis and Strata 14 was used to fit the meta-
regression models. Heterogeneity was assessed using 
both the Chi2 test and by evaluating the I2 value, which 
quantifies the percentage of total variation across studies 
that is due to heterogeneity rather than sampling error 
[26]. Univariate meta-regression models were fitted to 
assess if the effect size was significantly associated with 
mean age of the study population, gender (% male), 
whether the study was conducted on adults (>22  years) 
or adolescents (18–22  years), whether the participants 
had type 1 or type 2 DM, study design (cohort or cross-
sectional) and mean years smoked.
Results
In this systematic review, we conducted two types of 
analyses (narrative synthesis and meta-analysis), to com-
pare two groups of populations (smoker vs. non-smokers 
and smokers vs. quitters), on three types of outcomes 
(HbA1c, lipid profiles and blood pressure). In addition, 
we also conducted meta-regression analysis to explore 
the association between study effect size and study level 
covariates such as age, gender, whether the participants 
were adults or adolescents, types of diabetes, study 
design and duration of smoking.
Using the agreed search terms, we identified 6866 
articles on Medline, EMBASE, and CINAHL (Fig.  1). 
We reviewed 57 full-text articles, 16 of which met the 
inclusion criteria for the review and meta-analysis. 
Out of the 16 studies, 2 were excluded from the review; 
one of them was due to poor data quality [24] and the 
other one was because of participants’ resuming smok-
ing within 12 months of quitting [25]. All the 14 studies 
were included for narrative synthesis. Out of the 14, 12 
studies were cross-sectional while one study was a ret-
rospective and another was a prospective cohort study. 
10 studies were included for meta-analysis and the rest 
were excluded due to insufficient data. For smokers and 
non-smokers, we identified 10 studies for the outcome 
of HbA1c, 6 for lipid profile and 8 studies for blood 
pressure.
For smokers and quitters, only 4 out of 5 studies could 
be used for meta-analysis for the outcome of HbA1c. 
There was not enough data to pool the results for lipid 
profile and blood pressure for meta-analysis in this 
comparison groups. Full details of the study characteris-
tics are summarised in Tables 1, 2, 3 and 4. Meta-regres-
sion data and results are shown in Tables 5, 6, 7, 8, 9, 10 
and 11.
Smokers vs. non‑smokers
For the outcome of HbA1c, narrative synthesis was con-
ducted on smokers and non-smokers (n =  87,593). Out 
of the total study participants, 13,323 (15.21%) were 
smokers and 74,270 (84.79%) were non-smokers. 8 out of 
10 studies specified the gender of the study participants 
(45.94% male and 54.06% female). 9 out of 10 studies 
specified the type of diabetes of the study participants of 
whom 47.41% were people with T1DM and 49.67% were 
people with T2DM.
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Narrative synthesis
All the included studies demonstrated a close relationship 
between smoking, HbA1c, and lipid profiles in people 
with T1DM and T2DM (Figs. 2, 3, 4). However, there was 
no consistent relationship identified between blood pres-
sure and smoking status (Figs. 5, 6) In addition, smokers 
with T2DM were likely to be older, had longer duration of 
smoking history and poorer glycaemic control compared 
to non-smokers. Smokers have consistently shown lower 
HDL cholesterol and higher LDL cholesterol compared to 
non-smokers. Some studies suggested that smokers lose 
the natural nocturnal dip in blood pressure while some 
other studies found no diurnal variation in blood pres-
sure between smokers and non-smokers. Further study 
is needed to understand the exact relationship between 
smoking and blood pressure in people with diabetes.
Table 1 Study characteristics of smokers and non-smokers
Study Country No of participant Intervention/control Age/sex Included/excluded 
from meta‑analysis
Study designSmoker Non‑smoker Smoker Non‑smoker
Reynolds et al. [42] T2DM USA 414 66 348 18.6
39.4% M
15.6
35.6% M
Included
Cross sectional study
Reynolds et al. [42]T1DM USA 2327 203 2124 18.3
50.7% M
14.2
50.5% M
Included
Cross sectional study
Hofer et al. [43] T1DM Austria and Germany 27,561 4051 23,510 13.66
21.6% M
13.66
78.4% M
Included
Cross sectional study
Thomas et al. [44] T2DM China and Hong Kong 496 196 300 53.5
100% M
53
100% M
Included
Cross sectional study
Schwab et al. [45] T1DM Germany 92 19 73 15.9
100% F
11.7
100% F
Excluded (skewed data)
Cross sectional study
Wakabayashi et al. [46] T1 
and T2 DM
Japan 2563 1332 1231 52.15 54.7 Included
Cross sectional study
Hanesn et al. [47] T1DM Denmark 32 16 16 31
87.5% M
31
87.5% M
Included
Cross sectional study
Nilsson et al. [48] T1DM Sweden 11,513 1646 9867 41.3
47% M
40.8
55% M
Included
Cross sectional study
Nilsson et al. [48] T2DM Sweden 40,648 4512 36,136 61.1
61% M
68.4
53% M
Included
Cross sectional study
Gerber et al. [49] T2DM UK 763 603 160 35.1
71.3% M
36.1
52.1% M
Included
Prospective cohort study
Ohkuma et al. [50] T2DM Japan 1184 679 505 65.6 61.2 Included
Cross sectional study
Table 2 Study characteristics of smokers and quitters
Study Country No of  
participants
Exposure/control Age/sex Included or excluded 
from meta‑analysis
Study designSmoker Quitter Smoker Quitter
Lycett et al. [51] T2DM UK 10,692 7561 3131 61.6 (12.1)
58.4% M
61.6 (11.3)
64.4% M
Included
Retrospective cohort 
study
Iino et al. [52] T2DM Japan 31 16 15 60.1 (2.5)
81.25% M
62.7 (2.5)
80% M
Excluded (subjects 
started smoking 
within 12 months)
Prospective cohort 
study
Reynolds et al. [42] T2DM USA 125 66 59 18.6 (2.5)
39.4%
17.9 (2.4)
47.5% M
Included
Cross sectional study
Reynolds et al. [42] T1DM USA 412 203 209 18.3 (2.2)
50.7% M
17.7 (2.7)
47.4% M
Included
Cross sectional study
Ohkuma et al. [50] T2DM Japan 2490 679 1306 61.2 (10) 66.9 (9.2) Included
Cross sectional study
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HbA1c
Meta-analysis of the pooled data showed that the mean 
difference of HbA1c was −0.61% (95% CI −0.88 to −0.33, 
p  <  0.0001) between non-smokers and smokers (Fig  2). 
Meta-regression analyses showed that the observed dif-
ference in HbA1c levels between smokers and non-smok-
ers was significantly associated with the following factors: 
(a) mean age of study participants with the difference 
increasing with mean age (p  <  0.001); (b) whether the 
study was conducted on adults or adolescents partici-
pants, with the difference being larger in studies con-
ducted on adults (>22  years) as opposed to adolescents 
(18–22  years) (p  =  0.016); and c) the number of years 
smoked, with the difference increased as the duration of 
smoking increased (p = 0.034) (Table 6).
Lipid profiles
Meta-analysis of 6 studies with a total sample size of 
34,124 demonstrated that the difference in HDL-choles-
terol between non-smokers and smokers was 0.12 mmol/l 
(95% CI 0.08–0.15; p  <  0.001). Similarly, the difference 
in LDL-cholesterol between smokers and non-smokers 
was 0.11 (95% CI −0.21 to −0.01, p < 0.03) mmol/l. Both 
these results were statistically significant. Meta-regression 
examined whether the difference in HDL and LDL choles-
terol between smokers and non-smokers was linked with 
the mean age of study participants, whether the study was 
conducted on people with T1DM or T2DM, sex of the 
study participants, study design and duration smoked. No 
statistically significant correlation was detected with any 
of the above variables (Tables 7, 8).
Blood pressure
Meta-analysis of pooled data from 83,754 participants 
with type 1 or type 2 diabetes, showed no statistically 
significant differences in either SBP or DBP between 
smokers and non-smokers. The mean difference in SBP 
was −0.34  mm of Hg (95% CI −2.54 to 1.87, p =  0.77) 
and in DBP was −0.21 mm of Hg (95% CI –1.10 to 0.68, 
p = 0.64) in non-smokers and smokers, respectively.
Meta-regression analysis, however, showed that the 
mean difference in SBP was significantly associated with 
the mean age of the study participants (p = 0.030). Stud-
ies with older participants showed a larger difference in 
Table 5 Data used in meta-regression analyses
Study Mean age Participants 
age
Type 
of diabetes
% Male Study design Duration smoked
(mean years)
Pack years Years stopped
Gerber et al. [49] 35.9 Over 16 1 56 Cohort Not reported 21.6 Not reported
Hansen et al. [47] 31.9 Over 16 1 59 Cross-sectional 15.5 Not reported Not reported
Hofer et al. [43] 13.7 Under 22 1 52.5 Cross-sectional Not reported Not reported Not reported
Lycett et al. [51] 61.6 Over 16 2 60.2 Cohort Not reported Not reported Not reported
Nilsson et al. [48] 40.9 Over 16 1 53.8 Cross-sectional Not reported Not reported Not reported
Nilsson et al. [48] 67.6 Over 16 2 54 Cross-sectional Not reported Not reported Not reported
Ohkuma et al. [50] 65.1 Over 16 2 100 Cross-sectional 41.6 43.8 17.6
Reynolds et al. [42] 14.8 Under 22 1 50.2 Cross-sectional 4.5 Not reported Not reported
Reynolds et al. [42] 16.3 Under 22 2 37.6 Cross-sectional 2.1 Not reported Not reported
Thomas et al. [44] 53.2 Over 16 2 100 Cross-sectional Not reported Not reported Not reported
Wakabayashihi et al. 
[46]
53.4 Under 22 1 and 2 100 Cross-sectional Not reported Not reported Not reported
Table 6 Meta-regression analysis for  difference in  HbA1c 
between smokers and non-smokers
The italics values were to indicate statistical significance. A value of <0.05 was 
statitically significant
Covariate N studies Coefficient (95% CI) p value
Mean study age 10 0.02 (0.01, 0.02) <0.001
Study age criteria (under 22 
or over 18)
10 0.36 (−0.16, 0.89) 0.016
Type I or Type II diabetes 9 0.43 (−0.07, 0.93) 0.080
Male (percent) 10 0.01 (−0.00, 0.02) 0.101
Study design 10 −0.33 (−1.31, 0.65) 0.461
Duration smoked 4 0.021 (0.004, 0.038) 0.034
Table 7 Meta-regression analysis for  difference in  HDL 
between smokers and non-smokers
Covariate N studies Coefficient (95% CI) p value
Mean study age 6 −0.002 (−0.004, 0.000) 0.052
Study age criteria (under 
22 or over 18)
6 0.019 (−0.144, 0.016) 0.697
Type I or Type II diabetes 5 −0.08 (−0.19, 0.04) 0.119
Male (percent) 6 −0.001 (−0.003, 0.000) 0.053
Study design 6 −0.035 (−0.123, 0.193) 0.569
Duration smoked 6 Not enough observa-
tions
N/A
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SBP between smokers and non-smokers, compared to 
studies with younger participants. In relation to DBP, the 
mean difference between smokers and non-smokers was 
significantly greater in studies that had included adults 
(>22  years) as opposed to adolescents (18–22  years) 
(p =  0.041). In addition, difference in DBP was statisti-
cally significantly associated with percentage of partici-
pants who were male (p = 0.027), suggesting that studies 
with more male participants showed a larger difference 
in DBP between smokers and non-smokers (Tables 9, 10).
Smokers vs. quitters
To compare the outcomes of HbA1c, lipid profiles and 
blood pressure between smokers and quitters, 5 stud-
ies (n =  13,750) (3 cross-sectional, 1 prospective and 1 
retrospective design) were analysed. 63.32% of the study 
participants were continued smokers and 35.06% were 
quitters. 4 out of 5 studies specified the sex of the study 
population. In the continued smokers group 57.44% 
were male and 42.56% were female. In the quitter group, 
59.83% were male and 40.17% were female. 97% of the 
study participants had T2DM and 3% had T1DM.
Narrative synthesis
A narrative syntheses of the studies suggest that there 
was a graded relationship between smoking and quitting 
on HbA1c. There was a trend of a transient rise in HbA1c 
following quitting, which lasted from 1 to 3 years depend-
ing on the number of cigarettes consumed per day and 
pack-years smoked. Around 3  years after quitting, con-
tinued smokers and quitters had a similar level of HbA1c 
and around 10  years after quitting, the quitters’ HbA1c 
was comparable to never-smokers. One of the studies 
[27] conducted a univariate partial regression efficient 
and demonstrated that HbA1c declined linearly with the 
years after smoking cessation (p for trend <0.001).
On the other hand, the improvement in the lipid profile 
is almost instantaneous after quitting. As early as 3 weeks 
after quitting, the HDL cholesterol showed a trend to rise 
in quitters compared to continued smokers. There were 
insufficient data to make any comments about the out-
come of blood pressure following quitting. Meta-analysis 
was only possible for the outcome of HbA1c between 
continued smokers and quitters.
HbA1c
Meta-analysis of pooled data from 4 studies showed the dif-
ference of HbA1c between quitters and continued smokers 
was −0.10 (95% CI −0.42 to 0.21, p = 0.53) (Fig. 7) . This 
difference was not statistically significant. Meta-regression 
analysis did not show any statistically significant associa-
tion between study effect size and mean age of the study 
Table 8 Meta-regression analysis of LDL between smokers 
and non-smokers
Covariate N Studies Coefficient (95% CI) p value
Mean study age 6 0.003 (−0.009, 0.014) 0.052
Study age criteria (under 
22 or over 18)
6 0.067 (−0.365, 0.499) 0.691
Type I or type II diabetes 5 −0.05 (−0.74, 0.63) 0.825
Male (percent) 6 0.002 (−0.006, 0.010) 0.522
Study design 6 0.062 (−0.483, 0.608) 0.767
Duration smoked Not reported N/A N/A
Table 9 Meta-regression analysis for  difference in  SBP 
between smokers and non-smokers
Covariate N studies Coefficient (95% CI) p value
Mean study age 8 0.129 (0.017, 0.241) 0.30
Study age criteria (under 22 
or over 18)
8 4.51 (−0.68, 9.69) 0.078
Type I or Type II diabetes 8 2.46 (−3.84, 8.75) 0.377
Male (percent) 8 0.12 (−0.04, 0.29) 0.126
Study design 8 0.28 (−9.84, 10.41) 0.948
Duration smoked 3 0.36 (−3.92, 4.63) 0.482
Table 10 Meta-regression analysis for  difference in  DBP 
between smokers and non-smokers
The italic values were to indicate statistical significance. A value of <0.05 was 
statitically significant
Covariate N studies Coefficient (95% CI) p value
Mean study age 8 0.08 (−0.02, 0.17) 0.102
Study age criteria (under 22 
or over 18)
8 3.47 (0.02, 6.73) 0.041
Type I or Type II diabetes 8 1.26 (−3.36, 5.89) 0.529
Male (percent) 8 0.11 (0.02, 0.20) 0.027
Study design 8 0.57 (−6.55, 7.71) 0.850
Duration smoked 3 0.38 (−3.33, 4.09) 0.410
Table 11 Meta-regression analysis for difference in HbA1c 
between current and quitters
The italics values were to indicate statistical significance. A value of <0.05 was 
statitically significant
Covariate N studies Coefficient (95% CI) p value
Mean study age 4 0.01 (−0.02, 0.03) 0.432
Study age criteria (under 22 
or over 18)
4 0.36 (−1.06, 1.79) 0.391
Type I or type II diabetes 4 0.21 (−1.46, 1.89) 0.640
Male (percent) 4 0.001 (−0.035, 0.037) 0.909
Study design 4 0.40 (0.13, 0.66) 0.022
Duration smoked 3 0.003 (−0.063, 0.070) 0.628
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population (p = 0.432), whether the study participants were 
adults (>22 years) or adolescents (18–22 years) (p = 0.39), 
type of DM (p = 0.64), duration smoked (p = 0.62) and sex 
of the study participants (p = 0.90). However, there was a 
statistically significant association between effect size and 
study design (p = 0.02).
Fig. 2 Forest plots. HbA1c (smokers vs. non-smokers)
Fig. 3 Forest plots. HDL cholesterol (smokers vs. non-smokers)
Fig. 4 Forest plots. LDL-cholesterol (smokers vs. non-smokers)
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Fig. 5 Forest plots. Systolic blood pressure (smokers vs. non-smokers)
Fig. 6 Forest plots. Diastolic blood pressure (smokers vs. non-smokers)
Fig. 7 Forest plots. HbA1c (smokers vs. quitters)
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Discussion
The key findings of the review were non-smokers with dia-
betes had a lower level of HbA1c −0.61 (95% CI −0.88 to 
−0.33; p  <  0.001), a higher level of HDL cholesterol 0.12 
(95% CI 0.08 to 0.15; p < 0.001) and lower level of LDL cho-
lesterol −0.11 (95% CI −0.21 to −0.01; p = 0.03), compared 
to smokers. However, there was no statistically significant 
difference in either SBP or DBP between non-smokers 
and smokers −0.34 (95% CI −2.54 to 1.87; p = 0.77) and 
−0.21 (95% CI −1.10 to 0.68; p = 0.64), respectively. Uni-
variate adjusted meta-regression analyses revealed that 
for HbA1c, the difference is significantly associated with 
the mean age of the study population, whereby studies with 
an older population resulted in a larger difference in HbA1c 
between smokers and non-smokers 0.02 (95% CI 0.01, 0.02; 
p < 0.001). The study effect size was also significantly asso-
ciated with the duration of smoking 0.021 (95% CI 0.004 to 
0.038; p = 0.034) and whether the subjects were adults or 
adolescents 0.36 (95% CI −0.16 to 0.89; p =  0.016). Uni-
variate adjusted meta-regression analyses revealed that the 
relationship observed in HDL and LDL cholesterol in non-
smokers and smokers was not significantly associated with 
any of the study level covariates assessed. Whilst meta-
regression analysis did not show any significant association 
between SBP and study level covariates, but difference in 
DBP was significantly associated with the age of the study 
participants.
This review did not identify any statistically significant 
difference in HbA1c between smokers and quitters. The 
precise effect-size of quitting on lipid profiles and blood 
pressure could not be accurately delineated, as it was not 
possible to carry out the meta-analysis due to inadequate 
number of studies with available data. Conversely, this 
review did not show the expected reduction in HbA1c 
after smoking cessation despite overwhelming evidence 
that the insulin resistance improves after smoking cessa-
tion [28, 29].
The major weakness of this review is that it is carried 
out on observational studies and no temporal relation-
ship can be established. Due to the heterogeneity of study 
populations, the findings cannot be generalised. The out-
come of quitting for less than 12-months is unknown, as 
this study did not include quitters of less than 12-month 
duration of abstinence. Despite the outlined weaknesses, 
this is the first systematic review on this subject, which 
can be used as a useful tool to raise awareness about the 
current evidence on this topic of immense public health 
importance.
The detrimental effects of smoking in diabetes are 
well documented. It is estimated that cigarettes contain 
around 4000 chemicals of which, approximately 400 are 
considered to be harmful [30]. Inhalation is a very effi-
cient method of nicotine delivery, the compound gaining 
access to the key organs within seconds of administration 
[31]. After distribution in the circulation, nicotine trig-
gers a cascade of biochemical, hormonal, and metabolic 
disarray, which appears to be much more pronounced 
in people with diabetes [32, 33]. A recent study demon-
strated that nicotine infusion acutely impairs insulin sen-
sitivity in people with T2DM, but not in healthy subjects 
suggesting that smoking might affect people with diabe-
tes differently compared to people who do not have dia-
betes [34]. Several studies have confirmed that smokers 
with diabetes have a higher HbA1c and atherogenic lipid 
profiles compared to non-smokers [35, 36]. The relation-
ship of HbA1c and lipid profiles in this study can explain 
to a large extent the reason why smokers with diabe-
tes have a worse cardiovascular outcome compared to 
non-smokers.
A number of possible mechanisms, including metabolic 
deregulation, endothelial dysfunction, and alteration of 
plasma viscosity by interfering with the coagulation cas-
cade are suggested to explain the association between 
smoking and diabetes. Nicotine directly inhibits the 
binding of insulin receptor substrate (IRS) and prevents 
the activation of intracellular GLUT4, which in turn 
impedes intracellular glucose transport [37]. This action 
is followed by a compensatory rise in β-cell insulin secre-
tion as reflected by a higher circulating concentration of 
c-peptide in smokers, compared to non-smokers [38]. The 
findings of this review are complementary to the existing 
knowledge that smokers with diabetes have poorer cardi-
ometabolic profile compared to non-smokers.
However, our current understanding of the impact of 
quitting on cardiometabolic profile is vague. There are 
some anecdotal evidence suggesting that a transient 
rise in HbA1c takes place after smoking cessation [38, 
39], while some other studies indicate improved insulin 
sensitivity as early as 2  weeks after smoking cessation 
[29]. One of the possible explanations for this paradoxi-
cal relationship between the improved insulin sensitiv-
ity and a rise in HbA1c, could be a direct blunting effect 
of smoking on glycosylation of haemoglobin. In a study, 
researchers measured HbA1c in people without diabe-
tes from the original cohort of Framingham Heart Study 
and demonstrated that with increasing age and BMI, the 
HbA1c gradually increased over a period of 4–6  years. 
On the contrary, smokers did not show any such rise 
in HbA1c, suggesting that smoking might have a blunt-
ing effect on the glycosylation of haemoglobin [40]. It 
is, therefore, a possibility that after smoking cessation 
the blunting effect disappears and HbA1c value rises, 
without any actual deterioration of glycaemic control. 
Although this study did not show any statistically sig-
nificant change in HbA1c following quitting for the first 
3-years, but it found that if the abstinence continued 
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for 10  years, the HbA1c in quitters was comparable to 
never smokers. A WHO study showed there was an 
increase in mortality risk lasting for up to 10 years fol-
lowing quitting, which gradually declined to the level of 
non-smoker around 10 years after abstinence [30]. This 
increase in mortality rate may or may not be associated 
with a transient rise in HbA1c following quitting. As this 
systematic review showed there was a potential risk of 
worsening glycaemic control soon after quitting, we rec-
ommend that patients should be closely monitored for 
cardiovascular risk factors following smoking cessation.
It must be emphasized that the harmful effects of 
smoking are not limited to insulin resistance and poor 
glycaemic control. It is evident that cigarettes smoking, in 
addition to metabolic deregulations, plays a crucial role 
in endothelial dysfunction that contribute to increased 
cardiovascular mortality in smokers with diabetes. Ciga-
rettes release free radicals into the circulation, which 
triggers a chronic inflammatory response [31]. Over and 
above, nicotine and the free radicals alter plasma viscos-
ity by their action on circulating plasminogen activator 
and natural endothelial vasodilator nitric oxide [32, 33]. 
The collective outcome is atherosclerosis and a height-
ened sensitivity of the intrinsic coagulation cascade, 
which can lead to spontaneous thromboembolism [34]. 
It is, therefore, not inconceivable that smoking enhances 
vascular complications in diabetes not only by impaired 
glucose metabolism but also by several other concomi-
tant vascular perturbations.
Irrespective of the value of HbA1c, the cardiovascu-
lar mortality seems to improve after smoking cessation. 
ADVANCE (action in diabetes and vascular disease: pre-
terax and diamicron modified release controlled evalua-
tion) study has shown, despite moderate weight gain and 
transient rise in HbA1c, there was a 30% reduction in 
mortality after smoking cessation [35]. In Nurse’s Health 
study, the relative risk (RR) of coronary heart disease 
(CHD) in nurses with type 2 diabetes who had stopped 
smoking and remained abstinent for 10  years or over 
was similar to those who never smoked (RR 1.01; 95% CI 
0.73–1.38) [6]. After 10 years of abstinence, their HbA1c 
also dropped at the level of non-smokers.
Dyslipidemia is often associated with diabetes, which 
seems to be aggravated by smoking. Raised LDL cho-
lesterol is highly atherogenic, particularly with a low 
level of HDL cholesterol. Nicotine impairs the function 
of hepatic lipase, which in turns leads to atherogenic 
dyslipidemia [36]. Several studies have shown marked 
improvement in lipid profiles following quitting [37, 
38]. The HDL cholesterol starts rising as early as within 
17  days after quitting [21] and by 48  days there is up 
to about 15% increase in HDL cholesterol [39]. In this 
review, we have demonstrated that there was a rise in 
HDL cholesterol following smoking cessation, consistent 
with the current evidence.
The influence of smoking and quitting on blood pres-
sure in people with diabetes is not very well studied. 
Researchers using data from the Health Survey for Eng-
land for 3  years (1994–1996) examined the relationship 
between blood pressure and smoking status in people 
without diabetes [41]. This study was conducted on ran-
domly selected adults (n  =  33,860; 47% male) with BP 
measurements and smoking status (never, current and 
quitters) and was stratified into younger (age 16–44) and 
older (>45 years) age groups. After adjusting for age, BMI, 
social class and alcohol intake older male smokers had 
higher SBP compared to non-smokers. No such differ-
ence was observed (Additional file 3) in SBP in younger 
group and in DBP in either group. There was no statis-
tically significant difference observed between smokers 
and quitters for either SBP or DBP. This review did not 
find any statistically significant difference in blood pres-
sure between smokers, non-smokers and quitters sug-
gesting that the influence of smoking is similar on BP in 
people with and without diabetes. However, the older 
smokers may be at a higher risk of vascular complications 
compared to younger smokers, as their SBP seems to be 
higher.
Conclusion
In conclusion, this review demonstrated that smoking 
negatively impacts upon the cardiometabolic parameters 
in people with diabetes, which might have a significant 
detrimental influence on cardiovascular complications. 
Smoking cessation, on the other hand, improves the 
cardiometabolic profile particularly by raising cardio-
protective HDL cholesterol. However, the benefit of 
smoking cessation may not be immediately reflected on 
the HbA1c. The effects of nicotine should be viewed in 
the bigger context of overall cardiovascular milieu rather 
than HbA1c alone. Smoking cessation, on the other 
hand, can cause weight gain and transient rise in HbA1c. 
Therefore people with diabetes, when they stop smok-
ing, should be followed up very closely and their weight 
and HbA1c monitored. In addition, at the time of smok-
ing cessation, the healthcare professionals should offer 
appropriate support to modify lifestyles and consider 
intensifying pharmacotherapy to address the transient 
rise of HbA1c.
Additional files
Additional file 1: Database Search - EMBASE/CINAHL
Additional file 2: Database search - OVID/Medline
Additional file 3: Code for meta-regression
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